Market scenario:
Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.
The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.
The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.
Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.
Key Players
- Merck KGaA,
- Johnson & Johnson,
- AstraZeneca plc,
- Sanofi S.A.,
- Pfizer,
- Mylan N.V,
- Novartis AG,
- Teva pharmaceutical company,
- GlaxoSmithKline plc.
Segments
The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.
Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.
Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Regional Analysis
Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.
A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Access More Details of the Report @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922
Xanthoma Market Information: By Type (Xanthelasma, Xanthoma Tuberosum, Xanthoma Tendinosum, Eruptive Xanthoma), Diagnosis (Physical Examination, Biopsy, Blood Tests), Treatment (Drugs, Surgery), End User (Hospitals And Clinics) - Forecast Till 2027Market HighlightsXanthoma is a dermatology condition characterized by fatty growth underneath the skin.
The growth can vary in size ranging from a pinhead to as large as a grape and usually appear like a flat bump under the skin and sometimes yellow or orange colored.
The exact causes of xanthoma is unknown, however, genetic factors have been indicated a cause of this conditions such as cogenosis type 1a, autosomal recessive hypercholesterolemia, alagille syndrome, and cholesterol storage disease.High levels of blood lipids, or fats, hyperlipidemia, or high blood cholesterol levels, diabetes, cancer, hypothyroidism, biliary cirrhosis, cholestasis, nephrotic syndrome, hematologic diseases such as monoclonal gammopathy and other metabolic disorders are some of the risk factors of xanthoma.
However, the complications such as risk of bleeding, infections, pain, especially, during surgery, high cost of xanthoma treatment, and poor understanding of the disease may restrain the market growth.There is no preventive treatment for xanthoma which, is the single most unmet need in the market.
The market is expected to witness an exponential growth over the review period owing to technological advancement in surgical procedures.
Cost of the product is likely to a decisive factor in the developing regions such as Asia Pacific and, especially, Africa.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4860 Key Market PlayersSome of the key players profiled in the report are AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Bayer HealthCare Pharmaceuticals LLC, Pfizer, Inc., Novartis International AG, Teva pharmaceutical industries, Novo Nordisk, Sanofi and others.Regional AnalysisThe Americas accounts for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada.
Bioactive Fillings Market Research Report By Material (Silicon Dioxide Based, Calcium Oxide Based, Phosphorus Pentoxide Based, and Sodium Oxide Based), By Application (Orthopedic, Dental, Tissue Engineering), and By End-User - Global Forecast till 2027Market HighlightsBioactive fillings as the name suggests are bioactive materials and react with tissue surroundings as opposed to bio inert fillings resulting in biocompatability.
The market restraints are poor mechanical weakness, low fracture resistance, poor load-bearing capacity and mechanical strength, possible toxicity, high cost of bioactive fillings treatment, rejection of the bioactive fillings and others.Product development represents the best strategy for the market growth.
Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.Global Bioactive fillings Market PlayersSome of the key players profiled in the report are Septodont, Inc., DePuy Synthes, Medtronic, Stryker, Zimmer Biomet, SCHOTT AG, Aap Implantate AG, GNI GROUP LTD., Arthrex, Inc., Baxter, and others.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/937Regional AnalysisThe Americas account for a significant market share owing to high expenditure on the health care especially of the U.S. and Canada.
The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth.
Moreover, the large share of surgical restoration segment procedures in the returns of hospitals favors the market.
Germany is expected to be the fastest growing market over the assessment period due to its large medical devices industry and its large research base.Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period.
The healthcare businesses including all stakeholders are evolving rapidly and the future looks radically different from present.
People now have easy access to healthcare information, which keeps them updated.
Digitalization and integrated patient-centric approach is giving rise to databases, thus changing the nature of how healthcare operates.
Also, technologies like Artificial Intelligence, Additive manufacturing, and Machine Learning are acting as game changers in the healthcare industry, and will bring about major changes in incoming times.‘Healthcare is all about providing best services with superior patient outcomes.’ A Hospital chain that has proved just that is Wockhardt Hospitals (WHL).
Its main focus and aim being on clinical quality and patient-centric care, Wockhardt Hospitals are bridging the path through best medical practices, best nurses and doctors, best teams at par, best of the technology, and updated with the best medical practices.
To gain further insights into this journey full of innovation and patient care we bring you an exclusive interview with Zahabiya Khorakiwala who is theManaging Director and driving force behind this new-age chain of multi super-speciality Wockhardt Hospitals.
